PTC Therapeutics Stock

PTC Therapeutics EBITDA per Share

The EBITDA per Share of PTC Therapeutics (PTCT) as of Aug 19, 2026 is 10.61 USD. In the previous year, EBITDA per Share was -1.75 USD — a change of -705.29% (higher).

EBITDA per Share

10.61USD

YoY

-705.29%

Last updated:

EBITDA per Share of PTC Therapeutics is 2026 10.61 USD. EBITDA per Share of PTC Therapeutics was 2025 -1.75 USD. It decreases by -705.29% higher compared to the previous year.
Access this data via the Eulerpool API
Get Free API Key

PTC Therapeutics Stock analysis

What does PTC Therapeutics do? PTC Therapeutics Inc. is a biopharmaceutical company based in South Plainfield, New Jersey. The company was founded in 1998 and focuses on the research and development of drugs for the treatment of rare diseases. The company has two main divisions: product research and development, and science and innovation. Its product range includes several drugs for the treatment of rare diseases such as Duchenne muscular dystrophy, spinal muscular atrophy, and cystic fibrosis. One of its key products is Translarna, the first RNA-targeted drug approved for the treatment of Duchenne muscular dystrophy. Another product is Evrysdi, approved for the treatment of spinal muscular atrophy. PTC Therapeutics also has a pipeline of drugs being tested in clinical trials for various rare diseases. The company is committed to promoting innovation and has partnerships with academic institutions and other companies to explore and develop new therapies. Overall, PTC Therapeutics aims to improve the lives of patients with rare diseases through innovative treatments. PTC Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PTC Therapeutics stock

EBITDA per Share of PTC Therapeutics is 10.61 USD in 2026.

EBITDA per Share of PTC Therapeutics changed from -1.75 USD to 10.61 USD, representing a -705.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share PTC Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API
Get Free API Key

Income Statement — PTC Therapeutics

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — PTC Therapeutics